Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells

European Journal of Clinical Investigation

Volumn 35, Issue 11, 2005, Pages 700-710

  Vesely, B A ^a,b   Alli, A A ^a,b   Song, S J ^a,b   Gower Jr , W R ^a,b   Sanchez Ramos, J ^a,b   Vesely, D L ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cancer; Cyclic GMP; DNA synthesis; Natriuretic peptides; Peptide hormones; Therapeutics

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CELL DNA; HORMONE RECEPTOR; KALIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR C; PEPTIDE HORMONE; UNCLASSIFIED DRUG; VESSEL DILATOR PEPTIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CANCER MORTALITY; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS; HORMONE ACTION; HUMAN; HUMAN CELL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CELL COUNT; CELL LINE, TUMOR; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANYLATE CYCLASE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NATRIURETIC PEPTIDES; PEPTIDE FRAGMENTS; PROSTATIC NEOPLASMS; PROTEIN PRECURSORS; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 27844453822     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2005.01569.x     Document Type: Article

References (44)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Oh WK, Hurwitz M, D'Amico AV, Richie JP, Kantoff PW. Neoplasm of the prostate. In: Kufe DW, Pollock RE, Weicheslbaum RR, Bast RC Jr, Gansler TS, Holland JF et al., editors. Cancer Medicine. Hamilton, Ontario, Canada: BC Decker Inc;2003.pp. 1707-40.
3. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
4. Vesely DL, Clark LC, Garces AH, McAfee QW, Soto J, Gower WR Jr. Novel therapeutic approach for cancer using four cardiovascular hormones. Eur J Clin Invest 2004;34:674-82.
5. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SR, Gower WR Jr et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005;35:60-9.
6. Vesely BA, Fitz SR, Gower WR Jr, Vesely DL. Vessel dilator: Most potent of the atrial natriuretic peptides in decreasing the number and DNA synthesis of squamous lung cancer cells. Cancer Lett 2005, in press.
7. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli A, Solivan SR et al. Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 2005;35:388-98.
8. Gardner DG, Kovacic-Milivojevic BK, Garmai M. Molecular biology of the natriuretic peptides. In: Vesely DL, editor. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost; 1997.pp. 15-38.
9. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002;53:153-9.
10. Vesely DL. Natriuretic hormones. In: Alpern RJ, Hebert SC, editors. The Kidney: Physiology and Pathophysiology, 4th edn. San Diego, CA: Elsevier/Academic Press;2005.pp. XXX.
11. Vesely DL, Norris JS, Walters JM, Jespersen RR, Baeyens DA. Atrial natriuretic prohormone peptides 1-30, 31-67 and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987;148:1540-8.
12. 2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990;258:F1401-8.
13. 2. J Clin Invest 1992;89:1411-7.
14. Benjamin BA, Peterson TV. Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995;269:R1351-5.
15. + reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
16. Villarreal D, Reams GP, Taraben A, Freeman RH. Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1999;221:166-70.
17. Dietz JR, Scott DY, Landon CS, Nazian SJ. Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001;280:R1510-7.
18. Vesely DL, Douglass MA, Dietz JR, Gower WR Jr, McCormick MT, Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-40.
19. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G et al. Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994;78:1128-34.
20. Vesely DL, Dietz JR, Parks JR, Biag M, McCormick MT, Cintron G et al. Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998;98:323-9.
21. Vesely DL. Atrial Natriuretic Hormones. Englewood Cliffs, NJ: Prentice Hall; 1992.
22. Scotland RS, Ahluwalia A, Hobbs AJ. C-type natriuretic peptide in vascular physiology and disease. Pharmacol Ther 2005;105:85-93.
23. Lainchbury J, Richards AM, Nicholls MG. Brain natriuretic peptide in heart failure. In: Vesely DL, editor. Atrial Natriuretic Peptides. Trivandrum, India: Research Signpost; 1997.pp. 151-8.
24. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003;285:F167-77.
25. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
26. Vesely DL, Norsk P, Winters CJ, Rico DM, Sallman AL, Epstein M. Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989;192:230-5.
27. Hunter EFM, Kelly PA, Prowse C, Woods FJ, Lowry PJ. Analysis of peptides derived from proatrial natriuretic peptide that circulate in man and increase in heart disease. Scan J Clin Lab Invest 1998;58:205-16.
28. Franz M, Woloszczuk W, Horl WH. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000;58:374-8.
29. De Palo EF, Woloszczuk W, Meneghetti M, DePalo CB, Nielsen HB, Secher NH. Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000;46:843-7.
30. Franz M, Woloszczuk W, Horl WH. Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001;59:1928-34.
31. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostate carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
32. Fisher ER, Palekar A, Paulson JD. Comparative histopathologic, histochemical, electron microscopy and tissue culture studies of bronchial carcinoids and oat cell carcinomas of lung. Am J Clin Pathol 1978;69:165-72.
33. Gratzner HG. Monoclonal antibody to 5-bromo-ad 5-lodo-deoxyuridine: A new reagent for detection of DNA replication. Science 1982;218:474-5.
34. Yu CCW, Woods AL, Levison DA. The assessment of cellular proliferation by immunohistochemistry: A review of currently available methods and their applications. Histochem J 1992;24:121-31.
35. Morstyn G, Pyke K, Gardner J, Ashcroft R, deFazio A, Bhathal P. Immunohistochemical identification of proliferatory cells in organ culture using bromodeoxyuridine and a monoclonal antibody. J Histochem Cytochem 1986;34:697-701.
36. Qin Y, Williams G. Comparison of the classical autoradiographic and immunohistochemical methods with BrdU for measuring proliferation parameters in colon cancer. Anticancer Res 1993;13:731-6.
37. Waldman SA, Rapoport RM, Murad F. Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 1984;259:14332-4.
38. Vesely DL. Signal transduction: Activation of the guanylate cyclase-cyclic guanosine-3′5′ monophosphate system by hormones and free radicals. Am J Med Sci 1997;314:311-23.
39. Suga SI, Nakao K, Hosoda K, Mukoyama M, Ogawa Y, Shirakami G et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992;130:229-39.
40. Potter LR. Phosphorylation-dependent regulation of the guanylyl-cyclase-linked natriuretic receptor B: dephosphorylation is a mechanism of desensitization. Biochemistry 1998;37:2422-9.
41. Potter LR, Garbers DL. Protein kinase C-dependent desensitization of the atrial natriuretic peptide receptor is mediated by dephosphorylation. J Biol Chem 1994;269:14636-42.
42. Fan D, Bryan PM, Antos LK, Potthast RJ, Potter LR. Down-regulation does not mediate natriuretic peptide-dependent desensitization of natriuretic peptide receptor (NPR) -A or NPR-B: guanylyl cyclase-linked natriuretic peptide receptors do not internalize. Mol Pharmacol 2005;67:174-83.
43. Saba SR, Garces AH, Clark LC, Soto J, Gower WR Jr, Vesely DL. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 2005;53:989-95.
44. Chrisman TD, Schultz S, Potter LR, Garbers DL. Seminal plasma factors that cause large elevations in cellular cyclic GMP are C-type natriuretic peptides. J Biol Chem 1993;266:3698-703.